|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07D 491/048 | |
| A61K 31/4355 | |||
| A61P 3/04 | |||
| A61P 25/18 | |||
| A61P 25/22 | |||
| A61P 25/28 |
| (11) | Number of the document | 2146997 |
| (13) | Kind of document | T |
| (96) | European patent application number | 08742647.4 |
| Date of filing the European patent application | 2008-04-07 | |
| (97) | Date of publication of the European application | 2010-01-27 |
| (45) | Date of publication and mention of the grant of the patent | 2010-11-10 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2008/004533 |
| Date | 2008-04-07 |
| (87) | Number | WO 2008/127585 |
| Date | 2008-10-23 |
| (30) | Number | Date | Country code |
| 922851 P | 2007-04-11 | US |
| (72) |
CLEMENTS, Matthew, J., US
DEBENHAM, John, S., US
HALE, Jeffrey, J., US
MADSEN-DUGGAN, Christina, B., US
WALSH, Thomas, F., US
PERESYPKIN, Andrey, V., US
HELMY, Roy, US
|
| (73) |
Merck Sharp & Dohme Corp.,
126 East Lincoln Avenue, Rahway, NJ 07065,
US
|
| (54) | SUBSTITUTED FURO[2,3-B]PYRIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS |
| SUBSTITUTED FURO[2,3-B]PYRIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS |